Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metastatic osteosarcoma.

Najat C Daw1, Catherine A Billups, Carlos Rodriguez-Galindo

  • 1Department of Hematology-Oncology, St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee 38105-2794, USA. najat.daw@stjude.org

Cancer
|December 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educational Interventions for the Timely Diagnosis of Pediatric Patients With Cancer: A Scoping Review.

JCO global oncology·2026
Same author

Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across Europe.

JCO global oncology·2026
Same author

Ethnic and Socioeconomic Factors Associated with Locally Advanced Retinoblastoma: A Retrospective Study.

Ocular oncology and pathology·2026
Same author

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Blood advances·2026
Same author

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Blood advances·2026
Same author

Treatment Decision Making at Diagnosis for Children Presenting With Advanced Cancer in Low- and Middle-Income Countries.

JCO global oncology·2026
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
See all related articles

In metastatic osteosarcoma, carboplatin-based chemotherapy showed poorer survival than cisplatin-based regimens. Cisplatin is recommended for high-risk patients due to better outcomes despite toxicity.

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Cancer Chemotherapy

Background:

  • Analysis of two consecutive trials (OS-86 and OS-91) evaluating chemotherapy for metastatic osteosarcoma.
  • Comparison of cisplatin-based vs. carboplatin-based multiagent chemotherapy regimens.
  • Identification of prognostic factors influencing patient outcomes.

Purpose of the Study:

  • To assess the efficacy of carboplatin-based chemotherapy in metastatic osteosarcoma.
  • To compare outcomes between cisplatin (OS-86) and carboplatin (OS-91) containing regimens.
  • To identify prognostic indicators for improved survival in metastatic osteosarcoma.

Main Methods:

  • Retrospective analysis of 12 patients (OS-86) and 17 patients (OS-91) with metastatic osteosarcoma.
  • Treatment protocols included ifosfamide, cisplatin/carboplatin, doxorubicin, and methotrexate.

Related Experiment Videos

  • Patient data included demographics, tumor characteristics, and treatment response.

    • Main Results:

    • No significant demographic or disease characteristic differences between OS-86 and OS-91 cohorts.
    • A trend towards improved survival in the cisplatin-based OS-86 trial (P=0.054).
    • Favorable prognostic factors included unilateral lung metastases, limited nodules, and surgical remission.

    Conclusions:

    • The carboplatin-based regimen (OS-91) was associated with poorer outcomes compared to cisplatin (OS-86).
    • Cisplatin's use is justified in high-risk metastatic osteosarcoma despite its toxicity.
    • Lung-only metastases, limited tumor burden, and surgical remission predict better survival.